Introduction {#s1}
============

The prevalence of cardiovascular disease and stroke is increasing across the globe, as is the burden of these diseases ([@B21]; [@B2]). Chronic obstructive airway diseases include chronic obstructive pulmonary disease (COPD) and bronchiectasis. According to the 2015 Global Burden of Disease Study ([@B22]), COPD caused 3.2 million deaths worldwide in 2015. COPD is characterized by airflow limitation that is usually progressive and associated with persistent small airway inflammation, and it is a major risk factor for heart disease/stroke (HDS). A relatively recent study revealed that COPD with acute exacerbations is associated with an increased risk of cardiac arrhythmia with sudden death ([@B30]).

Bronchiectasis is a chronic respiratory disease characterized by a clinical syndrome of cough, sputum production, and bronchial infection, in addition to abnormal and permanent bronchial dilatation ([@B37]; [@B26]). Because of the increased use of high-resolution computed tomography (HRCT;[@B39]; [@B47]; [@B48]), the diagnostic sensitivity for bronchiectasis has increased ([@B40]). The clinical presentation of bronchiectasis overlaps with that of other respiratory disorders, such as asthma and COPD ([@B34]). For example, [@B38] examined computed tomography (CT) images obtained for patients and reported that 4%--72% of patients with severe COPD had radiological bronchiectasis; they also reported that 20%--30% of patients with severe or uncontrolled asthma had bronchiectasis.

A single-center study demonstrated an approximately three fold increase in the mortality rate of patients with bronchiectasis; specifically, patients with bronchiectasis and COPD had a 5-year mortality rate of 55% compared with the rate of 20% in those with bronchiectasis without COPD ([@B27]). Patients with bronchiectasis and COPD were also found to have an increased rate of acute respiratory events ([@B12]). Thus, bronchiectasis--COPD overlap syndrome (BCOS) may be considered a separate disorder ([@B6]; [@B36]). Treatments successful in managing COPD may not be as effective at managing bronchiectasis (and vice versa); this phenomenon is best exemplified by inhaled corticosteroids (ICSs). ICSs are widely used in COPD treatment but are not recommended for most patients with bronchiectasis. By contrast, inhaled antibiotics, including anti-pseudomonal agents in appropriate patients, are beneficial and appear in current bronchiectasis guidelines but are not used routinely in treating stable COPD ([@B27]).

Studies have yet to evaluate the effect of bronchodilator and ICSs/oral steroid (OSs) use on the risk of HDS in patients with BCOS. Current knowledge holds that the frequency of arrhythmias such as atrial fibrillation is high---up to 29%---in patients with COPD ([@B23]) and that anti-arrhythmia drugs play a role in the treatment of COPD with HDS ([@B42]). Therefore, in the present study, we investigated the effect of bronchodilator, ICSs/OSs, and antiarrhythmic drugs use on the risk of HDS in a cohort of patients with BCOS in comparison with a cohort of patients with COPD alone.

Methods {#s2}
=======

Data Source {#s2_1}
-----------

We used the Longitudinal Health Insurance Database 2000 (LHID2000), a subset of the National Health Insurance Research Database (NHIRD) established by the National Health Research Institutes (NHRI) in Taiwan. The NHRI reported no significant differences in the distribution of sex or age among beneficiaries in the LHID2000; thus, the database can be considered representative of the general population. The LHID2000 contains comprehensive information, including demographic data, all records of outpatient and inpatient hospital visits, complete prescription details, and diagnostic codes based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). For privacy protection, the personal identification numbers of all insurants were scrambled cryptographically to ensure anonymity before the data were released for research purposes. This study was exempted from a review by the Internal Review Board of China Medical University and Hospital (CMUH104-REC2-115-CR4).

Sample Patients {#s2_2}
---------------

To determine the prevalence of HDS in patients with bronchiectasis (ICD-9-CM code 494) and COPD (ICD-9-CM codes 491, 492, and 496), we selected a cohort of patients with BCOS who had two outpatient visits or an inpatient visit for BCOS and selected a comparable control cohort of patients without BCOS. For inclusion in the BCOS cohort, BCOS had to have been diagnosed between January 1, 2000, and December 31, 2012. ses of atients without BCOS was randomly selected from LHID2000 enrollees without any history of BCOS at a selection ratio of 1:1 based on 5-year intervals and according to sex, index year, sleep disturbance, pulmonary tuberculosis, pneumonia, asthma, diabetes mellitus, hypertension, hyperlipidemia, pulmonary embolism, and medication use (including use of LABAs, LAMAs, SABAs, SAMAs, ICSs, OSs, and anti-arrhythmia drugs) through propensity score matching. Those in the comparison cohort were paired with matching patients, and a month and day in the same year were randomly assigned as their index dates. Patients with a history of HDS before the index date were excluded from both study cohorts. All patients were followed up until they developed HDS, they died, they withdrew from the NHI program, or December 31, 2013, whichever occurred first.

Outcome and Medication {#s2_3}
----------------------

The primary outcome of this study was an individual event of heart disease (ICD-9-CM codes 410--414 and 425--429) or stroke (ICD-9-CM codes 433--434, 435, and 436). Data for underlying comorbidities, namely sleep disturbance (ICD-9-CM code 7805), pulmonary tuberculosis (PTB, ICD-9-CM codes 010--012), pneumonia (ICD-9-CM codes 481--483 and 485--486), asthma (ICD-9-CM code 493), diabetes mellitus (DM, ICD-9-CM code 250), hypertension (ICD-9-CM codes 401--405), and pulmonary embolism (ICD-9-CM code 415.1), were also collected. Furthermore, this study evaluated the effect of several drugs used for BCOS treatment on the risk of HDS, namely LABAs (Anatomical Therapeutic Chemical \[ATC\] codes R03AC12 and R03AC13), LAMAs (ATC code R03BB04), SABAs (ATC codes R03AC02, R03AC03, and R03AC04), SAMAs (ATC code R03BB01), ICSs (ATC codes R03BA01, R03BA02, R03BA05, and R03BA08), OSs (ATC codes D07AC15, R01AD05, H02AB02, D07AC17, S01BA02, H02AB04, H02AB06, H02AB08, and S01BA02), and anti-arrhythmia drugs (ATC code C01B). We accounted for several confounding factors, such as age, sex, comorbidities, and medication use.

Statistical Analysis {#s2_4}
--------------------

For each patient with BCOS, a matched control was assigned using propensity score matching to account for baseline differences between patients with and without BCOS. Demographic characteristics and the prevalence of comorbidities were compared using standardized mean difference, for which values of ≤0.10 were considered to indicate a negligible difference between two cohorts. We estimated the cumulative incidence of HDS for both the BCOS and comparison cohorts by using the Kaplan -- Meier method, and we examined the difference between the two curves by using the log-rank test. The Cox regression model was used to calculate the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for comparing the relative risk of HDS in the BCOS and non-BCOS cohorts. Comorbidities and drug use were included as covariates to account for potential confounding effects. We also analyzed the drug use days before HDS incidence to determine the effect of duration and dose on the risk of HDS in the BCOS cohort. Drug use days were categorized into the following subgroups: current use (drug use within 30 days of HDS incidence), recent use (drug use 30--90 days before HDS incidence), and past use (drug use \>90 days before HDS incidence). We used SAS software (version 9.4 for Windows; SAS Institute, Cary, NC) for all statistical analyses and Kaplan--Meier curves for survival analysis. A two-sided *P* value of \<0.05 was considered statistically significant.

Sensitivity Analysis {#s2_5}
--------------------

As noted in the previous section, three subgroups of drug use days (current, recent, and past) were defined. The cumulative DDD was analyzed to determine the effect of duration and dose on the risk of HDS in the BCOS cohort.

Validation of Bronchiectasis and COPD {#s2_6}
-------------------------------------

After observing HRCT scans, [@B38] determined that up to 3,521 of 7,156 patients were diagnosed as having bronchiectasis. On the basis of data from the NHIRD, [@B11] found that the following clinical presentations and tests were associated with a high diagnostic sensitivity for COPD: ever smoking (82.9%), cough with sputum (79%), chest X-ray (84.7%), pulmonary function testing (58.4%), and CT (39.4%). Recently, [@B25] validated the COPD cohort identified from the NHIRD in Taiwan; they determined that factors, including spirometry testing and diagnostic ICD-9-CM codes for COPD, increased the positive predictive value to 84.6%. This suggests that the BCOS results derived from the COPD cohort in the NHIRD are representative of patients with both bronchiectasis and COPD in the general population.

Results {#s3}
=======

After propensity score matching, we included 2,816 patients with COPD (1,412 women and 1,404 men) in our study cohort. The experimental cohort (n = 1,408) consisted of patients with BCOS (n = 1,186) and patients with both BCOS and asthma (n = 222). The control cohort (n = 1,408) consisted of patients with only COPD (n = 1,042) and patients with ACO (n = 366). The mean ages of the BCOS and non-BCOS cohorts were 59.0 ± 15.3 and 53.9 ± 20.4 years, respectively, and most of the patients were in the age range of 40--64 years. Compared with the BCOS cohort, the non-BCOS cohort had a higher proportion of patients with sleep disturbance, asthma, diabetes mellitus, hypertension, hyperlipidemia, LABAs use, SABAs use, SAMAs use, ICSs use, OSs use, and anti-arrhythmia drugs use ([**Table 1**](#T1){ref-type="table"}).

###### 

Baseline characteristics of the study population after propensity matching.

  Variables                   PS-matching population   Standardized mean differences^§^                 
  --------------------------- ------------------------ ---------------------------------- ------ ------ ------
  **Sex**                                                                                               
  female                      655                      46.5                               757    53.7   0.14
  male                        753                      53.5                               651    46.3   0.14
  **Age at baseline, year**                                                                             
  \<20                        15                       1.07                               95     6.75   0.29
  20--39                      138                      9.80                               230    16.3   0.19
  40--64                      726                      51.5                               637    45.2   0.12
  ≥65                         529                      37.6                               446    31.6   0.12
  mean(SD)                    59.01 (15.3)             53.96 (20.4)                       0.28          
  **Comorbidity**                                                                                       
  Sleep disturbance           16                       1.14                               69     4.90   0.22
  Pulmonary tuberculosis      128                      9.09                               162    11.5   0.08
  Pneumonia                   330                      23.4                               387    27.5   0.09
  Asthma                      222                      15.7                               366    25.9   0.25
  DM                          179                      12.7                               346    24.5   0.30
  Hypertension                230                      16.3                               299    21.2   0.12
  Hyperlipidemia              209                      14.8                               292    20.7   0.15
  Pulmonary embolism          3                        0.21                               4      0.28   0.01
  **Medication**                                                                                        
  LABAs                       154                      10.9                               168    11.9   0.03
  LAMAs                       37                       2.63                               25     1.78   0.05
  SABAs                       356                      25.2                               510    36.2   0.23
  SAMAs                       261                      18.5                               294    20.8   0.05
  ICSs                        234                      16.6                               317    22.5   0.14
  OSs                         673                      47.8                               776    55.1   0.14
  Anti-arrhythmics            27                       1.92                               55     3.91   0.11

COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.

^§^A standardized mean difference of ≤0.10 indicates a negligible difference between the two cohorts.

In this study, 780 patients developed HDS ([**Table 2**](#T2){ref-type="table"}). The incidence of HDS was higher in the patients with BCOS than in non-BCOS (5.65 and 3.26 per 100 person-years, respectively; aHR, 1.68; 95% CI, 1.45--1.94). The risk of HDS was higher in the BCOS cohort than in the non-BCOS cohort across both sex and age stratifications. Compared with patients without BCOS, patients with BCOS also had higher risk of HDS coupled with pulmonary tuberculosis (1.76-fold, 95% CI = 1.18--2.63), asthma (1.57-fold, 95% CI = 1.16--2.13), diabetes mellitus (1.57-fold, 95% CI = 1.16--2.13), hypertension (1.68-fold, 95% CI = 1.27--2.23), LABAs use (2.28-fold, 95% CI = 1.18--4.40), SABAs use (2.10-fold, 95% CI = 1.54--2.86), SAMAs use (2.73-fold, 95% CI = 1.85--4.02), ICSs use (2.57-fold, 95% CI = 1.67--3.96), and OSs use (1.85-fold, 95% CI, 1.49--2.31). By contrast, sleep disturbance, pneumonia, LAMAs use (aHR, 1.08; 95% CI, 0.28--4.06) and anti-arrhythmia drugs use (aHR, 2.78; 95% CI, 0.97--7.96) were not associated with a significantly increased risk of HDS.

###### 

Incidence rate and hazard ratio of stroke or heart-disease between the two groups stratified by gender, age, comorbidities and drug use after propensity matching.

  ----------------------------------------------------------------------------------------------------------------------------------------------------
                           Bronchiectasis - COPD   Crude HR\   Adjusted HR\                                                  
                                                   (95% CI)    (95% CI)                                                      
  ------------------------ ----------------------- ----------- -------------- ----- ------- ------ ------------------------- -------------------------
  **Overall**              340                     10,402      3.26           440   7,774   5.65   1.67 (1.45--1.92)\*\*\*   1.68 (1.45--1.94)\*\*\*

  **Gender**                                                                                                                 

  Female                   181                     5,692       3.17           188   3,835   4.90   1.48 (1.21--1.82)\*\*\*   1.57 (1.27--1.94)\*\*\*

  Male                     159                     4,710       3.37           252   3,939   6.39   1.83 (1.50--2.24)\*\*\*   1.82 (1.48--2.24)\*\*\*

  **Age**                                                                                                                    

  \< 20                    0                       915         0              0     148     0      --                        --

  20--39                   25                      2,160       1.15           15    1,037   1.44   1.27 (0.66--2.42)         3.47 (1.50--8.05)\*\*

  40--64                   151                     4,914       3.07           200   4,480   4.46   1.42 (1.15--1.76)\*\*     1.69 (1.35--2.12)\*\*\*

  ≥65                      164                     2,413       6.79           225   2,109   10.6   1.53 (1.25--1.87)\*\*\*   1.54 (1.25--1.90)\*\*\*

  **Comorbidity**                                                                                                            

  Sleep disturbance                                                                                                          

   No                      317                     9,798       3.23           431   7,680   5.61   1.66 (1.44--1.93)\*\*\*   1.71 (1.47--1.98)\*\*\*

   Yes                     23                      604         3.80           9     94      9.57   2.65 (1.22--5.76)\*       0.56 (0.18--1.77)

  Pulmonary tuberculosis                                                                                                     

   No                      287                     9,250       3.10           380   6,978   5.44   1.68 (1.44--1.96)\*\*\*   1.70 (1.45--1.99)\*\*\*

   Yes                     53                      1,152       4.60           60    796     7.53   1.61 (1.11--2.34)\*       1.76 (1.18--2.63)\*\*

   Pneumonia                                                                                                                 

   No                      213                     7,750       2.74           308   5,825   5.28   1.83 (1.54--2.18)\*\*\*   1.94 (1.62--2.34)\*\*\*

   Yes                     127                     2,652       4.78           132   1,949   6.77   1.39 (1.09--1.77)\*\*     1.18 (0.92--1.52)

   Asthma                                                                                                                    

   No                      254                     7,360       3.45           342   6,457   5.29   1.49 (1.26--1.75)\*\*\*   1.61 (1.36--1.92)\*\*\*

   Yes                     86                      3,042       2.82           98    1,317   7.44   2.50 (1.86--3.34)\*\*\*   1.57 (1.16--2.13)\*\*

   DM                                                                                                                        

   No                      218                     7,805       2.79           351   6,735   5.21   1.79 (1.51--2.13)\*\*\*   1.68 (1.41--2.00)\*\*\*

   Yes                     122                     2,597       4.69           89    1,039   8.56   1.79 (1.36--2.35)\*\*\*   1.66 (1.25--2.21)\*\*\*

   Hypertension                                                                                                              

   No                      234                     8,102       2.88           321   6,433   4.98   1.65 (1.40--1.96)\*\*\*   --

   Yes                     106                     2,300       4.60           119   1,341   8.87   1.88 (1.44--2.44)\*\*\*   1.68 (1.27--2.23)\*\*\*

   Hyperlipidemia                                                                                                            

   No                      227                     8,128       2.79           340   6,394   5.31   1.82 (1.54--2.16)\*\*\*   --

   Yes                     113                     2,274       4.96           100   1,380   7.24   1.42 (1.09--1.86)\*\*     1.45 (1.10--1.92)\*\*

  Pulmonary embolism                                                                                                         

   No                      339                     10,376      3.26           438   7,769   5.63   1.66 (1.44--1.92)\*\*\*   1.66 (1.44--1.92)\*\*\*

   Yes                     1                       26          3.84           2     5       40     --                        --

  **Medication**                                                                                                             

  LABAs                                                                                                                      

   Non-use                 323                     8,993       3.59           404   6,854   5.89   1.58 (1.36--1.83)\*\*\*   1.62 (1.39--1.88)\*\*\*

   Use                     17                      1,409       1.20           36    920     3.91   3.14 (1.76--5.62)\*\*\*   2.28 (1.18--4.40)\*

  LAMAs                                                                                                                      

   Non-use                 335                     10,201      3.28           432   7,587   5.69   1.67 (1.44--1.93)\*\*\*   1.68 (1.45--1.94)\*\*\*

   Use                     5                       201         2.48           8     187     4.27   2.06 (0.65--6.51)         1.08 (0.28--4.06)

  SABAs                                                                                                                      

   Non-use                 263                     6,329       4.15           334   5,630   5.93   1.37 (1.16--1.61)\*\*\*   1.56 (1.31--1.84)\*\*\*

   Use                     77                      4,073       1.89           106   2,144   4.94   2.59 (1.93--3.48)\*\*\*   2.10 (1.54--2.86)\*\*\*

  SAMAs                                                                                                                      

   Non-use                 296                     8,096       3.65           353   6,281   5.62   1.48 (1.26--1.72)\*\*\*   1.53 (1.31--1.80)\*\*\*

   Use                     44                      2,306       1.90           87    1,493   5.82   3.01 (2.09--4.33)\*\*\*   2.73 (1.85--4.02)\*\*\*

  ICSs                                                                                                                       

   Non-use                 302                     7,714       3.91           372   6,340   5.86   1.44 (1.24--1.68)\*\*\*   1.53 (1.31--1.79)\*\*\*

   Use                     38                      2,688       1.41           68    1,434   4.74   3.29 (2.21--4.90)\*\*\*   2.57 (1.67--3.96)\*\*\*

  OSs                                                                                                                        

   Non-use                 184                     4,343       4.23           241   3,716   6.48   1.44 (1.19--1.74)\*\*\*   1.57 (1.29--1.92)\*\*\*

   Use                     156                     6,059       2.57           199   4,058   4.90   1.89 (1.53--2.33)\*\*\*   1.85 (1.49--2.31)\*\*\*

  Anti-arrhythmia                                                                                                            

   Non-use                 325                     9,979       3.25           431   7,611   5.66   1.67 (1.45--1.93)\*\*\*   1.69 (1.45--1.96)\*\*\*

   Use                     15                      423         3.54           9     163     5.52   1.58 (0.69--3.63)         2.78 (0.97--7.96)
  ----------------------------------------------------------------------------------------------------------------------------------------------------

PY, person-years; IR, incidence rate, per 100 person-years; HR, hazard ratio; CI, confidence interval.

HR was adjusted for gender, age, sleep disturbance, pulmonary tuberculosis, pneumonia, asthma, diabetes mellitus, hypertension, hyperlipidemia, pulmonary embolism, LABAs-use, LAMAs-use, SABAs-use, SAMAs-use, ICSs-use, OSs-use, and anti-arrhythmia drugs use.

----Unable to calculate because of few or no events.

\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

[**Table 3**](#T3){ref-type="table"} presents the incidence and hazard ratios (HRs) of HDS stratified by drug use days in the BCOS and non-BCOS cohorts. Recent SABAs use, past ICSs use, and past anti-arrhythmia drugs use were significantly associated with a 32.2-fold (95% CI = 1.79--773.0), 1.85-fold (95% CI = 1.01--3.39), and 31.1-fold (95% CI = 3.25--297.8) higher risk of HDS in the BCOS cohort, respectively, compared with the non-BCOS cohort.

###### 

Incidence rate and hazard ratio of stroke or heart-disease between the two groups stratified by day of drug-use after propensity matching.

  ----------------------------------------------------------------------------------------------------------------------------------------------------
                           Bronchiectasis - COPD   Crude HR\   Adjusted HR\                                                  
                                                   (95%CI)     (95%CI)                                                       
  ------------------------ ----------------------- ----------- -------------- ----- ------- ------ ------------------------- -------------------------
  **Drug-use days**                                                                                                          

  LABAs                                                                                                                      

   Non use                 327                     9,031       3.62           424   6,923   6.12   1.63 (1.41--1.89)\*\*\*   1.62 (1.40--1.89)\*\*\*

   Current use (≤30 d)     0                       163         0              1     130     0.76   --                        --

   Recent use (30--90 d)   1                       82          1.21           1     47      2.12   2.56 (0.12--52.8)         --

   Past use (\>90 d)       12                      1,126       1.06           14    674     2.07   1.87 (0.86--4.06)         1.43 (0.53--2.93)

  LAMAs                                                                                                                      

   Non use                 337                     10,217      3.29           437   7,616   5.73   1.67 (1.45--1.93)\*\*\*   1.66 (1.44--1.93)\*\*\*

   Current use (≤30 d)     2                       35          5.71           0     20      0      --                        --

   Recent use (30--90 d)   1                       21          4.76           0     22      0      --                        --

   Past use (\>90 d)       0                       129         0              3     116     2.58   --                        --

  SABAs                                                                                                                      

   Non use                 286                     6,437       4.44           404   5.869   6.88   1.49 (1.28--1.73)\*\*\*   1.61 (1.37--1.88)\*\*\*

   Current use (≤30 d)     6                       345         1.73           6     212     2.83   1.61 (0.52--5.02)         1.98 (0.39--10.0)

   Recent use (30--90 d)   3                       211         1.42           4     105     3.80   2.61 (0.58--11.7)         32.2 (1.79--773.0)\*

   Past use (\>90 d)       45                      3,409       1.32           26    1,588   1.63   1.26 (0.78--2.05)         0.99 (0.58--1.67)

  SAMAs                                                                                                                      

   Non use                 312                     8,187       3.81           410   6,457   6.34   1.60 (1.38--1.85)\*\*\*   1.62 (1.39-1.89)\*\*\*

   Current use (≤30 d)     6                       272         2.20           5     110     4.54   1.96 (0.59-6.49)          1.75 (0.27-11.0)

   Recent use (30-90 d)    3                       148         2.02           4     82      4.87   2.92 (0.64--13.2)         --

   Past use (\>90 d)       19                      1,795       1.05           21    1,125   1.86   1.79 (0.96--3.33)         1.26 (0.62--2.52)

  ICSs                                                                                                                       

   Non use                 313                     7,777       4.02           409   6,461   6.33   1.52 (1.31--1.76)\*\*\*   1.52 (1.31--1.78)\*\*\*

   Current use (≤30 d)     0                       210         0              3     139     2.15   --                        --

   Recent use (30--90 d)   1                       100         1              1     60      1.66   2.55 (0.11--58.5)         --

   Past use (\>90 d)       26                      2,315       1.12           27    1,114   2.42   2.13 (1.24--3.65)\*\*     1.85 (1.01--3.39)\*

  OSs                                                                                                                        

   Non use                 300                     5,011       5.98           410   4,360   9.40   1.52 (1.31--1.76)\*\*\*   1.52 (1.30--1.77)\*\*\*

   Current use (≤30 d)     6                       727         0.82           8     628     1.27   1.74 (0.57--5.34)         2.12 (0.51--8.72)

   Recent use (30--90 d)   3                       512         0.58           6     439     1.36   2.53 (0.62--10.3)         2.13 (0.30--15.0)

   Past use (\>90 d)       31                      4,152       0.74           16    2,347   0.68   0.91 (0.50--1.67)         0.88 (0.46--1.66)

  Anti-arrhythmia                                                                                                            

   Non use                 330                     9,998       3.30           433   7,618   5.68   1.66 (1.43--1.91)\*\*\*   1.68 (1.45--1.94)\*\*\*

   Current use (≤30 d)     1                       34          2.94           1     36      2.77   0.76 (0.04--12.9)         --

   Recent use (30--90 d)   0                       19          0              0     0              --                        --

   Past use (\>90 d)       9                       351         2.56           6     120     5      2.10 (0.74--5.94)         31.1 (3.25--297.8)\*\*
  ----------------------------------------------------------------------------------------------------------------------------------------------------

\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

HR is adjusted for sex, age, sleep disturbance, pulmonary tuberculosis, pneumonia, asthma, diabetes mellitus, hypertension, hyperlipidemia, pulmonary embolism, LABAs-use, LAMAs-use, SABAs-use, SAMAs-use, ICSs-use, OSs-use, and anti-arrhythmia drug use.

---- Unable to calculate because of few or no events.

As indicated in [**Table 4**](#T4){ref-type="table"}, a low dose of SABAs (\< 1 DDD), medium dose of SABAs (1--20 DDD), low dose of SAMAs (\< 2 DDD), low dose of ICSs (\< 250 DDD), medium dose of ICSs (250--420 DDD), low dose of OSs (\< 4 DDD), and medium dose of OSs (4--14 DDD) were significantly associated with a 2.12-fold (95% CI = 1.46--3.10), 3.48-fold (95% CI = 1.13--10.6), 3.19-fold (95% CI = 2.04--4.99), 28.1-fold (95% CI = 14.2--555.7), 2.09-fold (95% CI = 1.32--3.29), 2.28-fold (95% CI = 1.53--3.40), and 1.93-fold (95% CI = 1.36--2.74) higher risk of HDS in the BCOS cohort, respectively, relative to the non-BCOS cohort.

###### 

Incidence rate and hazard ratio of stroke or heart-disease between the two groups stratified by cumulative drug dosage after propensity matching.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
                                Bronchiectasis - COPD   Crude HR\   Adjusted HR\                                                  
                                                        (95% CI)    (95% CI)                                                      
  ----------------------------- ----------------------- ----------- -------------- ----- ------- ------ ------------------------- -------------------------
  **Cumulative dose of drug**                                                                                                     

  LABAs (DDD) (µg/d)                                                                                                              

   Non-use                      323                     8,993       3.59           404   6,855   5.89   1.58 (1.36--1.83)\*\*\*   1.62 (1.39--1.88)\*\*\*

   \<210                        3                       595         0.50           11    227     4.84   9.78 (2.69--35.5)\*\*\*   --

   210--420                     14                      814         1.71           22    677     3.24   1.83 (0.93--3.60)         1.11 (0.50--2.44)

   \>420                        0                       0                          3     15      20     --                        --

  LAMAs (mg/d)                                                                                                                    

   Non-use                      335                     10,201      3.28           432   7,587   5.69   1.67 (1.44--1.93)\*\*\*   1.68 (1.45--1.94)\*\*\*

   \<1                          2                       82          2.43           0     32      0      --                        --

   1--30                        0                       0                          0     0              --                        --

   \>30                         3                       119         2.52           8     155     5.16   2.26 (0.59--8.64)         2.01 (0.42--9.54)

  SABAs (mg/d)                                                                                                                    

   Non-use                      263                     6,329       4.15           334   5,630   5.93   1.37 (1.16--1.61)\*\*\*   1.56 (1.31--1.84)\*\*\*

   \<1                          54                      2,538       2.12           70    1,243   5.63   2.62 (1.83--3.74)\*\*\*   2.12 (1.46--3.10)\*\*\*

   1--20                        8                       498         1.60           14    220     6.36   4.04 (1.68--9.74)\*\*     3.48 (1.13--10.6)\*

   \>20                         15                      1,037       1.44           22    681     3.23   2.20 (1.14--4.25)\*       1.73 (0.78--3.85)

  SAMAs (mg/d)                                                                                                                    

   Non-use                      296                     8,097       3.65           353   6,281   5.62   1.48 (1.26--1.72)\*\*\*   1.53 (1.31--1.80)\*\*\*

   \<2                          38                      1,883       2.01           51    812     6.28   3.08 (2.02--4.69)\*\*\*   3.19 (2.04--4.99)\*\*\*

   2--20                        0                       37          0              2     18      11.1   --                        --

   \>20                         6                       385         1.55           34    663     5.12   3.15 (1.32--7.52)\*\*     2.31 (0.75--7.15)

  ICSs (µg/d)                                                                                                                     

   Non-use                      302                     7,714       3.91           372   6,340   5.86   1.44 (1.24--1.68)\*\*\*   1.53 (1.31--1.79)\*\*\*

   \<250                        2                       508         0.39           7     184     3.80   9.13 (1.88--44.1)\*\*     28.1 (1.42--555.7)\*

   250--420                     36                      2,120       1.69           59    1,239   4.76   2.73 (1.80--4.15)\*\*\*   2.09 (1.32--3.29)\*\*

   \>420                        0                       60          0              2     11      18.1   --                        --

  OSs (mg/d)                                                                                                                      

   Non-use                      184                     4,344       4.23           241   3,716   6.48   1.44 (1.19--1.74)\*\*\*   1.57 (1.29--1.92)\*\*\*

   \<4                          54                      2,385       2.26           60    1,038   5.78   2.53 (1.75--3.67)\*\*\*   2.28 (1.53--3.40)\*\*\*

   4--14                        57                      2,345       2.43           85    1,897   4.48   1.81 (1.30--2.54)\*\*\*   1.93 (1.36--2.74)\*\*\*

   \>14                         45                      1,328       3.38           54    1,123   4.80   1.39 (0.93--2.07)         1.34 (0.84--2.14)

  Anti-arrhythmia (mg/d)                                                                                                          

   Non-use                      325                     9,980       3.25           431   7,612   5.66   1.67 (1.45--1.93)\*\*\*   1.69 (1.45--1.96)\*\*\*

   \<30                         0                       0                          0     0              --                        --

   30--35                       11                      366         3.00           7     114     6.14   2.12 (0.80--5.62)         3.95 (0.83--18.6)

   \>35                         4                       57          7.01           2     48      4.16   0.59 (0.10--3.50)         --
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; PY, person-years; IR, incidence rate, per 1,000 person-years; HR, hazard ratio; CI, confidence interval; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

HR is adjusted for gender, age, sleep disturbance, pulmonary tuberculosis, pneumonia, asthma, diabetes mellitus, hypertension, hyperlipidemia, pulmonary embolism, LABAs-use, LAMAs-use, SABAs-use, SAMAs-use, ICSs-use, OSs-use, and anti-arrhythmia drugs use.

-- Unable to calculate because of few or no events.

[**Figure 1**](#f1){ref-type="fig"} presents Kaplan--Meier curves for HDS risk stratified by the two cohorts and compared using a log-rank test. BCOS was associated with a significantly increased risk of HDS events (log-rank P \< 0.001). From the first year of follow-up to the end of the study period, the incidence of HDS events in the BCOS cohort was higher than that in the non-BCOS cohort.

![Kaplan--Meier curves of overall survival for the patients both with and without bronchiectasis-COPD (log-rank p \< 0.0001).](fphar-10-01409-g001){#f1}

Indication and Healthy User Bias {#s3_1}
--------------------------------

In this study, we analyzed LABAs/LAMAs, SABAs/SAMAs, ICSs/OSs and anti-arrhythmia drugs use in the BCOS cohort to determine the effect of these drugs on the risk of HDS in this population. We excluded all patients with a history of bronchiectasis and COPD diagnosis and drug use before the diagnosis of BCOS. Accordingly, all patients included in the BCOS cohort were new users of the mentioned drugs. We classified these patients according to drug use days into the following subgroups before HDS incidence: current, recent, and past. Thus, we could analyze the effects of the drugs on the current, recent, and past users in the BCOS cohort. Furthermore, BCOS severity may be a confounding factor of drug use, with patients with more severe BCOS receiving higher drug doses. To resolve this problem, we analyzed the DDD to determine how different doses of a drug may affect the risk of HDS ([@B46]).

Discussion {#s4}
==========

This general population study resulted in four major findings. First, patients with BCOS, even those without comorbidities, had a higher risk of HDS. [@B35] Second, recent SABAs use, past ICSs use, and past anti-arrhythmia drugs use were associated with a relatively high risk of HDS. Third, a low to medium dose of SABAs, ICSs, or OSs and a low dose of SAMAs were associated with a relatively high risk of HDS. Fourth, LAMAs were not significantly associated with HDS risk.

[@B43] reported that the initiation (\< 30 days) of LABAs or LAMAs in patients with COPD was associated with an approximately 1.5-fold increase in severe cardiovascular risk, irrespective of prior HDS status or history of exacerbation. In the present study, we found that LAMAs were not associated with HDS. Evidence from observational studies supports the possible link between the use of LABAs/LAMAs for COPD management and HDS, although confounding and bias cannot be entirely ruled out for the positive findings. Moreover, although randomized controlled trials (RCTs) have not documented that LABAs/LAMAs therapy in patients with COPD is associated with an elevated risk of HDS, null findings may result from insufficient statistical power, the exclusion of patients at a high risk of HDS, and failure to account for the use of other respiratory medications during follow-up. The role of LABAs/LAMAs in the risk of HDS among patients with BCOS remains controversial ([@B44]). Future RCTs and observational studies are urgently required to address the noted limitations and clarify how these drugs affect HDS risk.

Recent use and low or medium doses of SABAs are associated with a higher risk of HDS. According to one previous study ([@B33]), SABAs administration resulted in hypoxemia, a paradoxical reaction ([@B41]); this paradoxical reaction may explain the higher risk of HDS associated with SABAs use ([@B17]). Hypoxemia was also associated with an increased wall-area percentage of segmental airways (odds ratio \[OR\] = 1.04, 95% CI = 1.01--1.08), in addition to being independently associated with aggravated dyspnea, a shorter 6-min walking distance, a higher BODE (Body mass index, airflow Obstruction, Dyspnea, and Exercise) index, and a greater frequency of exacerbation ([@B3]). BCOS is a disorder combined with these poor indices. Consequently, the inappropriate use of SABAs may aggravate hypoxemia and promote HDS development ([@B17]).

Bronchiectasis and COPD are airway and system inflammation diseases. BCOS is a disorder that combines both of these diseases. Thus, patients with BCOS have a higher level of system inflammation ([@B13]), whic corresponds to poor lung function and quality score ([@B7]; [@B15]). This high level of inflammation combined with hypoxemia contributes to the atherosclerosis of the arteries in patients with BCOS, meaning that atherosclerosis-related HDS incidents ([@B20]) occur at a higher rate in patients diagnosed as having both bronchiectasis ([@B19]) and COPD. The limited anti-inflammatory effects ([@B28]; [@B29]) of LABAs/LAMAs, SABAs/SAMAs, and ICSs/OSs means that these drugs may have difficulty ameliorating the progress of persistent arterial atherosclerosis. However, in this study, a high DDD of OSs was not associated with HDS risk. One possible explanation for this is that patients exhibiting the eosinophilic phenotype of BCOS may have favorable responses to these drugs, which may thus attenuate the risk of HDS ([@B16]).

Previous studies have found that use of OSs, whether current, recent, or past, did not coincide with a high risk of HDS. However, low to medium doses of OSs may be associated with a high risk of HDS. BCOS is a disorder with an immunocompromised component, which aggravates immunodeficiency. The system effect of OSs contributes to hyperglycemia, hypertension, and hyperlipidemia development, which are predisposing factors for HDS. Thus, OSs use is associated with HDS development, as discovered in the present study. Accordingly, steroids should not be routinely used in BCOS treatment ([@B18]).

We also found that although anti-arrhythmia drugs use were generally associated with a higher risk of HDS, a medium DDD of 30--36 did not increase the risk of HDS. This is consistent with the finding of [@B8]; [@B9] that anti-arrhythmia drugs used as rhythm or rate control agents in arrhythmia treatment were associated with a reduction in cardiovascular risk. These findings imply that past or optimal doses of anti-arrhythmia drugs may attenuate the risk of incident HDS.

Finally, patients with BCOS have a poor prognosis ([@B14]); hence, such patients, particularly those who frequently use SABAs, SAMAs, or OSs in the later course of BCOS treatment, have higher mortality rates compared with other patients ([@B17]). However, because these patients have a shorter life-spans, they are also at a lower risk of HDS. Therefore, past use or high doses of SABAs (aHR, 1.73; OR, 0.78--3.85), SAMAs (aHR, 2.31; OR, 0.75--7.15), or OSs (aHR, 1.34; OR, 0.84--2.14) were not associated with HDS. This finding may represent an underestimation of the risk of HDS in these groups. Moreover, patients who frequently use these drugs are more likely to strictly adhere to the medical directions provided for them, which may also serve to limit the incidence of HDS ([@B49]). This implies that LAMAs; optimal time; and the dose of SABAs, SAMAs, or OSs in patients with mild to moderate BCOS may provide protective effects against acute incident HDS. However, this speculation warrants further research.

Although RCTs can produce valuable information, they are associated with several drawbacks: they require a substantial amount of money, results obtained from animal experiments are not completely applicable to humans, and human trials can have considerable ethical complications in the real world. For example, we cannot routinely prescribe the long-term use of anti-arrhythmia drugs to patients with BCOS without consulting an expert (e.g., a cardiologist). Currently, the long-term prescription of ICSs and LABAs is strictly controlled by cardiologists in Taiwan.

Furthermore, the new LAMAs added on the ICSs/LABAs associated with the increased risk of HDS among COPD cohort in the finding of the [@B32]. Our study revealed that recent use of SABAs was associated with the higher risk of HDS and LAMAs were not associated with the HDS. These findings alert the physician to detect the risk of the HDS in the recent use of SABAs and encourage the physician to early use of the LAMAs among the BCOS cohort. Meanwhile, the frequency of the BCOS cohort receiving the LAMAs was higher than the non-BCOS cohort in this study.

The comparision cohort (non-BCOS) including the ACO. Therefore, the non-BCOS cohort having the higher frequency of receiving the medicine such as LABAs, SABAs, SAMAs, and ICSs/OSs than the BCOS cohort ([@B45]; [@B46]; [@B49]).

This large-scale study explored the effect of bronchodilator, ICSs/OSs, and anti-arrhythmia drugs use on the risk of HDS in the BCOS cohort based on the large scale. Our results may serve as a reference for the future research (e.g., RCTs) of the BCOS. Thus, if the BCOS is considered as a different separate entity disease; our study may offer useful information for providing the appropriate and personalized medicine in patients with BCOS. ([**Appendix Figure 1**](#SM1){ref-type="supplementary-material"})

Strengths {#s4_1}
---------

The accuracy of the medical records in the NHIRD is high; therefore, this database is a valuable resource for population research on cardiovascular disease and stroke ([@B10]). [@B25] validated the COPD cohort from the NHIRD. Thus, the BCOS cohort extracted from the NHIRD is reasonable. Moreover, the NHIRD-based identification of COPD ([@B25]) and bronchiectasis-related diseases, such as pulmonary tuberculosis and pneumonia, has been validated in several recent reports ([@B25]; [@B45]; [@B46]). Therefore, the use of this well-established database limits the potential bias in this study. We also carefully followed up each of the patients studied (for 5.51 ± 4.02 years for the patients in the BCOS cohort and for 7.79 ± 4.2 years for the patients in the non-BCOS cohort). Our long-term follow-up process may be more beneficial than that performed in RCTs, particularly when studying older patients or patients who have multiple comorbidities ([@B4]). As mentioned, we analyzed the effects of treatment duration and dose on the risk of HDS. Our methods may help avoid the confounding factors typically found in cohort studies.

Limitations {#s4_2}
-----------

Possible limitations of this study are biases and confounding variables, such as choice of exposure risk window or confounding by indication. Risk windows can be validated or a sensitivity analysis may be conducted based on varying lengths of exposure risk windows---here, we analyzed the DDD of the drugs examined. For confounding by indication, randomization helps to prevent selection bias by a clinician, and we included the frequency of outpatient or inpatients visits. Another potential limitation is protopathic bias, which can be controlled by adding a lag time to the exposure (e.g., excluding exposure that occurred in a period before the outcome within HDS). We analyzed the risk of HDS in patients within 30 to 90 days and \>90 days of drug use. Finally, surveillance bias is also a concern. Evidence-based clinical guidelines should specify which at-risk patients must be studied and should clearly convey exact testing modalities and frequencies. In our study, we analyzed patients with and without comorbidities ([@B31]; [@B24]).

We used several designs and factors to control for bias and confounding variables: new user design (entry after cohort), case-only design (past, recent, current), and disease risk score (frequency of outpatient and inpatient visits). Within this framework, these methods are similar to those utilized in RCTs. However, our results are not as accurate as those that would have been obtained from an RCT ([@B24]). In addition, cytokine data are unavailable in the NHIRD. We used a new user approach to evaluate healthy user bias. However, data on lifestyle changes (e.g., exercise and diet) in low- or high-adherence patients are unavailable in the NHIRD; these confounding factors may have led to some biases in the present study.

Our asthma--COPD--bronchiectasis subcohort was derived from the COPD cohort of the NHIRD. Because the treatment principle of this subcohort was observed to be similar to that of the bronchiectasis--COPD subcohort ([@B1]), we enrolled the bronchiectasis--COPD subcohort as the BCOS cohort and considered the asthma--COPD--bronchiectasis cohort as a distinct entity within the BCOS cohort. Thus, we may list this subcohort as another confounding factor of our study.

Conclusion {#s5}
==========

Compared with patients without bronchiectasis--COPD, patients with BCOS with recent SABAs use, past ICSs use, past anti-arrhythmia drugs use, a low or medium SABAs dose, a low or medium ICSs dose, a low or medium OSs dose, and a low SAMAs dose had a higher risk of HDS. LAMAs were not associated with HDS risk.
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